Invention Grant
- Patent Title: PD-L1 and OX40 binding proteins for cancer Regulation
-
Application No.: US16871799Application Date: 2020-05-11
-
Publication No.: US11643470B2Publication Date: 2023-05-09
- Inventor: Jhong-Jhe You , Ching-Hsuan Hsu , Po-Lin Huang , Hung-Tsai Kan , Ting-Yi Chang , Hsin-Ta Hsieh , Jeng-Horng Her
- Applicant: AP Biosciences, Inc.
- Applicant Address: TW Taipei
- Assignee: AP Biosciences, Inc.
- Current Assignee: AP Biosciences, Inc.
- Current Assignee Address: TW Taipei
- Agency: The Webb Law Firm
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00

Abstract:
Provided are monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. Exemplary proteins release the inhibition through PD-L1 and stimulate T cell through OX40. Exemplary polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, the binding sites may be linked through an immunoglobulin constant region. Anti-OX40 and anti-PD-L1 antibodies are also provided.
Public/Granted literature
- US20200270357A1 Monospecific and Bispecific Proteins with Immune Checkpoint Regulation for Cancer Therapy Public/Granted day:2020-08-27
Information query